A relevant topic in the healthcare space that has arisen amid the COVID-19 pandemic is the alarming drop in cancer screening rates globally due to limited access of patients to hospitals settings and cancellations of non-elective procedures, which will inevitably result in increased cancer deaths in coming years. The pandemic has reemphasized the relevance of the advancement of patient-friendly solutions that can help diagnose the warning signs of cancer effectively, while also reducing the need of hospital visits and invasive procedures. I believe that, in 2021, we will continue to see efforts from biotech and medical technology companies to improve performance of current patient-friendly screening tools, to offer increased sensitivity and specificity while ensuring patient compliance. For some cancers, such as colorectal cancer, this is particularly relevant, since screening for and later removal of benign colorectal polyps can in fact prevent development of the disease and later cancer.